Because management were disingenuous about the efficacy of HER-VAXX, which led to many holders losing huge paper and cash amounts.
I've expressed my concerns with CF33 previously. The data will speak for itself. Fortunately, there is a huge literature base for the efficacy of Keytruda to compare a combination trial to.
I wonder why Merc pulled out of the partnership where IMU would give away a major share of their IP. Must have been because they saw such positives signs.
Ann: Next cohort reached in IV arms of CF33-hNIS (VAXINIA) study, page-63
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 5.1¢ | 5.1¢ | 4.8¢ | $1.062M | 21.65M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 5138497 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 6291273 | 3 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |